Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts. Show more

321 HARRISON AVENUE, BOSTON, MA, UNITED STATES, 02118, Boston, MA, 02118, USA

BIOTECHNOLOGY

HEALTHCARE

Market Cap

184.4M

52 Wk Range

$0.97 - $5.55

Previous Close

$2.92

Open

$2.95

Volume

636,480

Day Range

$2.80 - $3.00

Enterprise Value

162.2M

Cash

7.238M

Avg Qtr Burn

-26.0M

Insider Ownership

13.60%

Institutional Own.

42.83%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Micvotabart pelidotin (MICVO, formerly PYX-201) + KEYTRUDA® (pembrolizumab) Details Advanced Solid Tumors (various)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Micvotabart pelidotin (MICVO, formerly PYX-201) Details Cancer, 2L/3L R/M HNSCC [Arms: EGFRi+PD(L)-1-experienced; platinum/PD(L)-1-experienced]	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYX-106 Details Colorectal cancer , Kidney cancer, Bladder cancer, Cholangiocarcinoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.